--- title: "From GLP-1 Hype to Tokenization Mirages: Hong Kong's Fringe Market is a Wild Ride" type: "News" locale: "en" url: "https://longbridge.com/en/news/294038781.md" description: "Forget the blue chips. This eclectic mix of Hong Kong equities reveals how desperate companies are pivoting in 2026. From biomedical breakthroughs in weight-loss drugs to questionable blockchain pivots, the noise-to-signal ratio here is deafening." datetime: "2026-07-28T09:12:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294038781.md) - [en](https://longbridge.com/en/news/294038781.md) - [zh-HK](https://longbridge.com/zh-HK/news/294038781.md) generator: "portal-rs" --- # From GLP-1 Hype to Tokenization Mirages: Hong Kong's Fringe Market is a Wild Ride Let’s be honest: tracking the fringes of the Hong Kong market right now feels like wandering through a chaotic bazaar where everyone is shouting a different buzzword to see what sticks. You want weight-loss drugs? You want blockchain? You want... premium tea? It’s all here, and it is a fascinating, messy reflection of what companies will do to catch a bid in 2026. Take the sudden biomedical flex of 银诺医药 (2591.HK). They just pushed out China’s first domestic GLP-1 drug this January. I’ve said it before, and I'll say it again: the weight-loss drug craze is the new gold rush. Being the third globally to commercialize this kind of product puts them right in the crosshairs of a massive market shift. But while they are legitimately chasing the future of metabolic health, others are making baffling pivots. Look at 亦辰集团 (8365.HK) — a traditional professional services firm that suddenly decided it needs to explore "tokenization" and Real World Assets (RWA) in the Greater Bay Area. Spoiler alert: whenever a legacy consultancy starts throwing around crypto jargon, you should probably hold onto your wallet. Then you have the sheer randomness of consumer and industrial plays trying to find their footing. 八马茶业 (6980.HK) is leaning hard into the premium tea market, boasting a H1 2026 profit jump of over 60%. Insiders have been accumulating shares, which is usually a rare sign that they actually believe their own pitch. Meanwhile, 荣尊国际 (1780.HK) just watched a mandatory cash offer collapse in July because the shareholders basically said, "No thanks." It's exactly the kind of corporate drama that gets ignored by the mainstream but tells you everything about the lack of liquidity and enthusiasm in these corners. And what about the heavy industry stalwarts? 中国大冶有色 (0661.HK) is still digging copper and gold out of Mongolia and the mainland, entirely disconnected from the tech hype cycle, just doing the dirty work. 远大中国 (2789.HK) and 赛迪顾问 (8050.HK) are playing the long game in their respective lanes, with the latter recently busy talking up Hong Kong's integration into the national industrial system at Beijing forums. Good luck with that structural transition. The rest? It’s a mix of companies keeping their heads down. 阜丰集团 (2637.HK) and 天虹纺织 (2635.HK) are essentially radio silent, riding out the macroeconomic turbulence without making a splash. And then there’s WT 集团 (8450.HK), passing around the hat with a 1-for-2 rights issue that barely scraped together a 48% acceptance rate in July. It’s a tough crowd out there. Listen, if you’re playing in this sandbox, you better know exactly what you’re digging for, because the noise-to-signal ratio is absolutely deafening. ### Related Stocks - [02591.HK](https://longbridge.com/en/quote/02591.HK.md) - [02637.HK](https://longbridge.com/en/quote/02637.HK.md) - [08050.HK](https://longbridge.com/en/quote/08050.HK.md) - [06980.HK](https://longbridge.com/en/quote/06980.HK.md) - [02635.HK](https://longbridge.com/en/quote/02635.HK.md) - [08365.HK](https://longbridge.com/en/quote/08365.HK.md) - [01780.HK](https://longbridge.com/en/quote/01780.HK.md) - [02789.HK](https://longbridge.com/en/quote/02789.HK.md) - [08450.HK](https://longbridge.com/en/quote/08450.HK.md) ## Related News & Research - [Guangzhou Innogen Pharmaceutical Launches HK$50 Million H-Share Buyback Plan](https://longbridge.com/en/news/296976816.md) - [Fujian Haixi Pharma says FDA grants fast track status to HX9428 for wet AMD](https://longbridge.com/en/news/296099932.md) - [Nuobikan Secures RMB50.8 Million AI Software Deal With Leading Chip Provider](https://longbridge.com/en/news/295091547.md) - [BUZZ-Fujian Haixi jumps on initial approval of HX9428 for macular degeneration treatment](https://longbridge.com/en/news/294911244.md) - [Haixi Pharmaceuticals Advances Oral nAMD Drug HX9428 With U.S. FDA Nod and New China Trial](https://longbridge.com/en/news/294800012.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**